Cargando…
Metformin Treatment Reduces CRC Aggressiveness in a Glucose-Independent Manner: An In Vitro and Ex Vivo Study
SIMPLE SUMMARY: In 2020, colorectal cancer (CRC) was ranked third among the most common cancers in the world, and second in terms of cancer-related mortality. Epithelial–mesenchymal transition (EMT) is mainly recognized by the loss of epithelial markers (such as E-cadherin) and cell movement activat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378121/ https://www.ncbi.nlm.nih.gov/pubmed/37509386 http://dx.doi.org/10.3390/cancers15143724 |
_version_ | 1785079687559512064 |
---|---|
author | Boutaud, Marie Auger, Clément Verdier, Mireille Christou, Niki |
author_facet | Boutaud, Marie Auger, Clément Verdier, Mireille Christou, Niki |
author_sort | Boutaud, Marie |
collection | PubMed |
description | SIMPLE SUMMARY: In 2020, colorectal cancer (CRC) was ranked third among the most common cancers in the world, and second in terms of cancer-related mortality. Epithelial–mesenchymal transition (EMT) is mainly recognized by the loss of epithelial markers (such as E-cadherin) and cell movement activation, partially due to extracellular matrix remodeling by metalloproteinases, such as MMP2 and MMP9. It constitutes a critical step that promotes the spread of cancerous cells in oncogenesis, especially in epithelial cancers like CRC. Metformin is an anti-diabetic drug used in the treatment of type 2 diabetes; it targets mitochondrial metabolism and APMK. The EMT inhibitory effect from metformin used in the treatment of type 2 diabetic patients has been studied in large cohorts of patients with different cancer types; however, the mechanism of protection from metformin to colorectal cancer spread is still unknown, especially in the context of non-diabetes. Sortilin is a poor prognostic marker in CRC that may be related to signaling pathways that metformin could downregulate. This study focuses on the metformin-mediated effect on colorectal cancer aggressiveness according to different glucose conditions. ABSTRACT: (1) Background: Metformin, an anti-diabetic drug, seems to protect against aggressive acquisition in colorectal cancers (CRCs). However, its mechanisms are still really unknown, raising questions about the possibility of its positive impact on non-diabetic patients with CRC. (2) Methods: An in vitro study based on human colon cancer cell lines and an ex vivo study with different colon cancer stages with proteomic and transcriptomic analyses were initiated. (3) Results: Metformin seems to protect from colon cancer invasive acquisition, irrespective of glucose concentration. (4) Conclusions: Metformin could be used as an adjuvant treatment to surgery for both diabetic and non-diabetic patients in order to prevent the acquisition of aggressiveness and, ultimately, recurrences. |
format | Online Article Text |
id | pubmed-10378121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103781212023-07-29 Metformin Treatment Reduces CRC Aggressiveness in a Glucose-Independent Manner: An In Vitro and Ex Vivo Study Boutaud, Marie Auger, Clément Verdier, Mireille Christou, Niki Cancers (Basel) Article SIMPLE SUMMARY: In 2020, colorectal cancer (CRC) was ranked third among the most common cancers in the world, and second in terms of cancer-related mortality. Epithelial–mesenchymal transition (EMT) is mainly recognized by the loss of epithelial markers (such as E-cadherin) and cell movement activation, partially due to extracellular matrix remodeling by metalloproteinases, such as MMP2 and MMP9. It constitutes a critical step that promotes the spread of cancerous cells in oncogenesis, especially in epithelial cancers like CRC. Metformin is an anti-diabetic drug used in the treatment of type 2 diabetes; it targets mitochondrial metabolism and APMK. The EMT inhibitory effect from metformin used in the treatment of type 2 diabetic patients has been studied in large cohorts of patients with different cancer types; however, the mechanism of protection from metformin to colorectal cancer spread is still unknown, especially in the context of non-diabetes. Sortilin is a poor prognostic marker in CRC that may be related to signaling pathways that metformin could downregulate. This study focuses on the metformin-mediated effect on colorectal cancer aggressiveness according to different glucose conditions. ABSTRACT: (1) Background: Metformin, an anti-diabetic drug, seems to protect against aggressive acquisition in colorectal cancers (CRCs). However, its mechanisms are still really unknown, raising questions about the possibility of its positive impact on non-diabetic patients with CRC. (2) Methods: An in vitro study based on human colon cancer cell lines and an ex vivo study with different colon cancer stages with proteomic and transcriptomic analyses were initiated. (3) Results: Metformin seems to protect from colon cancer invasive acquisition, irrespective of glucose concentration. (4) Conclusions: Metformin could be used as an adjuvant treatment to surgery for both diabetic and non-diabetic patients in order to prevent the acquisition of aggressiveness and, ultimately, recurrences. MDPI 2023-07-22 /pmc/articles/PMC10378121/ /pubmed/37509386 http://dx.doi.org/10.3390/cancers15143724 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Boutaud, Marie Auger, Clément Verdier, Mireille Christou, Niki Metformin Treatment Reduces CRC Aggressiveness in a Glucose-Independent Manner: An In Vitro and Ex Vivo Study |
title | Metformin Treatment Reduces CRC Aggressiveness in a Glucose-Independent Manner: An In Vitro and Ex Vivo Study |
title_full | Metformin Treatment Reduces CRC Aggressiveness in a Glucose-Independent Manner: An In Vitro and Ex Vivo Study |
title_fullStr | Metformin Treatment Reduces CRC Aggressiveness in a Glucose-Independent Manner: An In Vitro and Ex Vivo Study |
title_full_unstemmed | Metformin Treatment Reduces CRC Aggressiveness in a Glucose-Independent Manner: An In Vitro and Ex Vivo Study |
title_short | Metformin Treatment Reduces CRC Aggressiveness in a Glucose-Independent Manner: An In Vitro and Ex Vivo Study |
title_sort | metformin treatment reduces crc aggressiveness in a glucose-independent manner: an in vitro and ex vivo study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378121/ https://www.ncbi.nlm.nih.gov/pubmed/37509386 http://dx.doi.org/10.3390/cancers15143724 |
work_keys_str_mv | AT boutaudmarie metformintreatmentreducescrcaggressivenessinaglucoseindependentmanneraninvitroandexvivostudy AT augerclement metformintreatmentreducescrcaggressivenessinaglucoseindependentmanneraninvitroandexvivostudy AT verdiermireille metformintreatmentreducescrcaggressivenessinaglucoseindependentmanneraninvitroandexvivostudy AT christouniki metformintreatmentreducescrcaggressivenessinaglucoseindependentmanneraninvitroandexvivostudy |